With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space episode artwork

EPISODE · Feb 20, 2025 · 22 MIN

With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space

from BiotechTV - News · host BiotechTV

Herriot Tabuteau updates us on the commercialization of Auvelity and Sunosi, launch plans for the recently approved Symbravo, as well as numerous NDA filings and data readouts that Axsome has coming up over the near term. Plus, how he thinks about business development and the big picture.

Episode metadata supplied by the publisher feed · Published Feb 20, 2025

Embed this episode

Ready to play

With three approved products and filings for more over the near term, Axsome's CEO describes the scale and reach this company is building in the CNS space

0:00 22:46

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 22 minutes long.

When was this BiotechTV - News episode published?

This episode was published on February 20, 2025.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!